Experimental HIV vaccine trial halted early – what we know

NCT ID NCT05470400

First seen Apr 30, 2026 · Last updated May 14, 2026 · Updated 1 time

Summary

This early-stage study tested whether a new HIV vaccine was safe and could trigger an immune response in healthy adults aged 18 to 50. The vaccine was given alone or with other HIV vaccines in different schedules. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Atlanta - Hope Clinic

    Atlanta, Georgia, 30308, United States

  • BIDMC Vcrs [32077]

    Boston, Massachusetts, 02115, United States

  • Columbia P&S CRS [30329]

    New York, New York, 30329, United States

  • New York Blood Center CRS [31801]

    New York, New York, 10065, United States

  • University of Pittsburgh CRS [1001]

    Pittsburgh, Pennsylvania, 15213, United States

  • University of Rochester Vaccines to Prevent HIV Infection CRS [31467]

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.